As ITIH5 might keep prognostic information for bladder cancer risk stratification, while ECRG4 showed a convincing diagnostic performance, in particular in combination with the known biomarker candidate NID2, both biomarkers, ECRG4 and ITIH5, may be promising candidates to complete and improve current biomarker panels and platforms. Here, ECRG4 is linked to urinary bladder cancer.